Latham & Watkins LLP represented Jefferies LLC in the transaction. Goodwin Procter LLP advised Unum Therapeutics Inc on the deal.
Concurrent with the acquisition of Kiq, Unum Therapeutics entered into a definitive agreement for the sale of Series A non-voting convertible Preferred Stock in a private placement to a group of institutional accredited investors led by Fairmount Funds Management LLC, with participation from Venrock Healthcare Capital Partners, BVF Partners L.P., Atlas Venture, Acorn Bioventures, Perceptive Advisor’s LLC, RTW Investments, OrbiMed, Samsara BioCapital, Logos Capital, Ally Bridge Group and Commodore Capital, as well as additional undisclosed institutional investors.
The private placement is expected to result in gross proceeds to Unum of approximately $104.4 million before deducting placement agent and other offering expenses.
Unum Therapeutics Inc. is a biopharmaceutical company focused on developing therapies for solid tumors.
Jefferies is a diversified financial services company engaged in investment banking and capital markets, asset management and direct investing.
Latham & Watkins LLP represented Jefferies LLC, the lead placement agent for the private placement, in the transaction with a New York-based team led by partner Nathan Ajiashvili, with associates Roger Yarett and Victoria McGrath.
The Goodwin team advising on the acquisition was led by Andrew Goodman (Picture), and included Nicole Daley, Tevia Pollard and Stephanie Dworkin.
The Goodwin team advising on the investment was led by Danielle Lauzon and included Stephanie Richards,Nicole Daley and Kyra Ayo Caros.
Involved fees earner: Kyra Ayo Caros – Goodwin Procter; Nicole Daley – Goodwin Procter; Stephanie Dworkin – Goodwin Procter; Andrew Goodman – Goodwin Procter; Danielle Lauzon – Goodwin Procter; Tevia Pollard – Goodwin Procter; Stephanie Richards – Goodwin Procter; Nathan Ajiashvili – Latham & Watkins; Victoria McGrath – Latham & Watkins; Roger Yarett – Latham & Watkins;